Recent Data Shows Prophylaxis Is Initiated at a Younger Age for Patients With Severe Hemophilia
Researchers sought to determine whether there were any changes in prophylactic treatment practices among previously untreated patients with hemophilia.
Researchers sought to determine whether there were any changes in prophylactic treatment practices among previously untreated patients with hemophilia.
Researchers sought to determine the role of the A1 domain of the VWF glycoprotein in VWF tubule assembly.
Researchers sought to assess the impact of problem joints in patients with hemophilia.
Researchers sought to determine whether a mismatch between F8 gene haplotypes impacted antibody binding to factor VIII in patients with hemophilia A.
Researchers sought to evaluate effects of kinesiophobia among patients with hemophilia.
Researchers sought to assess the risk of progression to ITP or hematologic neoplasia in adults with persistent, isolated mild thrombocytopenia.
Researchers sought to determine whether emicizumab would be effective in treating infants with severe hemophilia A without factor VIII inhibitors.
Researchers sought to determine whether using factor VIII concentrate with an extended half-life would improve outcomes in patients with hemophilia A.
Post-hoc analysis of XTEND-1 data measured the effects of efanesoctocog alfa prophylaxis on physical function and health-related quality of life in patients with hemophilia A.
Researchers sought to investigate whether health care providers investigated heavy menstrual bleeding as a potential symptom of an underlying bleeding disorder.